Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Accuray Incorporated (ARAY : NSDQ)

• Company Description    Accuray Inc. designs, develops & sells radiosurgery and radiation therapy systems for treatment of tumors in the body. The company's product suite includes the CyberKnife Systems and the TomoTherapy Systems. It primarily generates revenues by selling the CyberKnife & TomoTherapy Systems and providing ongoing services and upgrades to customers following installation of the CyberKnife System. Product revenues include sales of linacs for other uses. It also offers optional hardware and software, technical enhancements and upgrades to the CyberKnife & TomoTherapy System. The CyberKnife Systems include: the CyberKnife G4, CyberKnife VSI System and the new CyberKnife M6 Series System. TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical intensity modulated radiation therapy; the TomoHD System and the Tomo H Series Systems. Number of Employees: 987

• Price / Volume Information    Yesterday's Closing Price: $1.41 Daily Weekly Monthly 20 Day Moving Average: 769,312 shares Shares Outstanding: 103.01 (millions) Market Capitalization: $145.25 (millions) Beta: 1.26 52 Week High: $2.95 52 Week Low: $1.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.80% 8.58% 12 Week -4.73% -19.86% Year To Date -28.79% -33.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1240 Deming Way - MADISON,WI 53717 USA ph: 608-824-2800 fax: 408-716-4601 aman.patel@westwicke.com http://www.accuray.com

• General Corporate Information    Officers Suzanne Winter - Chief Executive Officer; President and Director Joseph E. Whitters - Chairperson of the Board Ali Pervaiz - Chief Financial Officer Robert C. Kill - Director Byron C. Scott - Director Peer Information Accuray Incorporated (ABMD) Accuray Incorporated (DMDS) Accuray Incorporated (CPWY.) Accuray Incorporated (EQUR) Accuray Incorporated (ECIA) Accuray Incorporated (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 004397105 SIC: 3841 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 103.01 Most Recent Split Date: (:1) Beta: 1.26 Market Capitalization: $145.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.92 Price/Cash Flow: - Price / Sales: 0.31 EPS Growth vs. Year Ago Period: 83.33% vs. Previous Quarter: -150.00% Sales Growth vs. Year Ago Period: 11.98% vs. Previous Quarter: -2.52% ROE 06/30/25 - - 03/31/25 - 1.43 12/31/24 - -9.75 ROA 06/30/25 - - 03/31/25 - 0.14 12/31/24 - -0.93 Current Ratio 06/30/25 - - 03/31/25 - 1.64 12/31/24 - 1.62 Quick Ratio 06/30/25 - - 03/31/25 - 0.92 12/31/24 - 0.88 Operating Margin 06/30/25 - - 03/31/25 - 0.14 12/31/24 - -0.96 Net Margin 06/30/25 - - 03/31/25 - 0.14 12/31/24 - -0.96 Pre-Tax Margin 06/30/25 - - 03/31/25 - 0.63 12/31/24 - -0.47 Book Value 06/30/25 - - 03/31/25 - 0.48 12/31/24 - 0.48 Inventory Turnover 06/30/25 - - 03/31/25 - 2.17 12/31/24 - 2.06 Debt-to-Equity 06/30/25 - - 03/31/25 - 3.35 12/31/24 - 3.51 Debt-to-Capital 06/30/25 - - 03/31/25 - 77.02 12/31/24 - 77.81

Powered by Zacks Investment Research ©